ELTX - CIK 0001601485
Elicio Therapeutics, Inc. trades as ELTX. This page tracks Elicio Therapeutics, Inc. through 360 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -2781.5% to -1225.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| Annual report (amended) | 10-K/A | 2026-04-29 |
| EFFECT | - | 2026-03-16 |
| Prospectus supplement | 424B5 | 2026-03-16 |
| Major company event | 8-K | 2026-03-16 |
| S-3/A | - | 2026-03-12 |
| Employee stock plan | S-8 | 2026-03-12 |
The largest companies sharing Elicio Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year Elicio Therapeutics, Inc. reported a net loss of $39.57M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.